Dermatopathology and Clinic: Telangiectasia Macularis Eruptiva Perstans

The study analyzed data from the Phase III AMAGINE-2 and -3 trials to assess the effectiveness of brodalumab versus ustekinumab in treating psoriasis using absolute PASI scores. Results showed that brodalumab was more effective, with a higher probability of patients achieving and maintaining a response (absolute PASI = 0 or ≤2) over 52 weeks. Specifically, 81% of patients on brodalumab were in response at Week 52 compared to 60% on ustekinumab. Additionally, the mean time in response was longer for brodalumab (215 days) than for ustekinumab (145 days), indicating brodalumab's superior efficacy in managing psoriasis.